全球肌肉松弛剂市场 – 行业趋势和 2030 年预测

肌肉松弛剂市场分析及规模

肌肉松弛剂通常用作手术期间的麻醉剂，并长期用于重症监护病房患者的控制机械通气。据报道，在几名患者中，镇静是常见的不良反应。因此，医生通常建议在服用肌肉松弛剂后不要驾驶或操作重型机械。COVID-19 疫情的突然爆发导致全球实施了严格的封锁规定，导致全球肌肉松弛剂市场的进出口活动中断。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球肌肉松弛剂市场的增长率。在上述预测期内，全球肌肉松弛剂市场的预期复合年增长率趋于 7.50% 左右。2022 年市场价值为 16.8 亿美元，到 2030 年将增长至 30 亿美元。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

肌肉松弛剂市场范围和细分

Market Definition

Muscle relaxants are commonly used during surgery to prevent muscle movement. They are structurally similar to acetylcholine and cause muscle relaxation by minimizing muscle tension. Some muscle relaxant works on the brain or spinal cord to decrease or block excessively stimulated nerve pathways. These types of muscle relaxants are known as a centrally-acting muscle relaxants.   

Global Muscle Relaxant Market Dynamics

Drivers

• Rising Prevalence of Musculoskeletal Issues

The increasing prevalence of musculoskeletal problems and rising customer awareness of their treatment and management boost the market's growth. Structurally distinct medications are the recent technologically improved muscle relaxants that are used to soothe muscle spasms, discomfort, and hyperreflexia. This boosts the growth of the market.

•  Growing Elderly Population

Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies. Thus, this population demands high use of muscle relaxants and boosts market growth.

Opportunities

• Growing Prevalence of Lower Back Pain

According to the records of the World Health Organization (WHO), the non-specific burden of lower back pain has increased significantly globally, which is estimated at 60–70% in industrialized countries, whereas the one-year occurrence rate increased rate 15–45%, adult prevalence 5% per annum and mostly incidence of lower back pain has seen in above 35 age bracket people. Thus, this factor demands more drugs and, as a result, is increasing the market's growth.

• Major Developments by the Market Players

There are numerous developments done by major market players that are boosting the growth of the market. For instance, in September 2019, Ipsen Biopharmaceuticals received U.S. FDA approval for expanded use of Dysport (abobotulinumtoxinA) as an injection to treat children two years of age and older having upper limb spasticity excluding spasticity caused by cerebral palsy. Thus, this leads to market expansion.

Restraints/Challenges

• Adverse Side-Effects of Muscle Relaxants

There are severe side effects related to muscle relaxants, such as dizziness, dry mouth, tiredness, and depression which restrict the market growth.

• High Investment and Strict Regulatory Norms

The growth of the muscle relaxant market is limited by factors such as strict regulatory requirements and the risks associated with muscle relaxants. Being a complex process, the use, separation, and development of raw materials for developing pharmaceutical and biopharmaceutical drugs demand professional and qualified personnel. Thus, all these factors restrict the growth of the demand for muscle relaxant drugs.

This global muscle relaxant market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global muscle relaxant market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Muscle Relaxant Market

Musculoskeletal pain is witnessed to be the commonest problem in routine medical practice. Most pain sources are associated with muscles or fascia becoming damaged, which then triggers pain. Though COVID-19 primarily affects the lungs and internal organs, musculoskeletal injury from this disease was visible due to marked elevation in creatine kinase and lactate dehydrogenase levels. Moreover, pain management during the COVID-19 pandemic demands attention due to difficulties in accessing hospitals for medical services such as physical therapy and rehabilitation. Thus, COVID-19 left a major impact on global muscle relaxant market.

Recent Developments

• In June 2022, Amneal Pharmaceuticals launched LYVISPAH, which is a baclofen oral granules specialty product approved by the U.S. FDA for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.
• In January 2022 Amneal Pharmaceuticals acquired Saol's Baclofen franchise, including Lioresal and LYVISPAH and a pipeline product under development. The acquisition expands the company's commercial, institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.

Global Muscle Relaxant Market Scope

The global muscle relaxant market is segmented on the basis of type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Skeletal Muscle Relaxant
• Neuromuscular Relaxant
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Muscle Relaxant Drugs Market Regional Analysis/Insights

The global muscle relaxant market is analysed and market size insights and trends are provided by type, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the global muscle relaxant market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period due to the rise cases of surgical procedures performed annually and increase prevalence of due to the increased R&D activities on muscle relaxant and well-established health care infrastructure in the region. 

Asia-Pacific is dominating the market due to increased advancement in the technology and growth and expansion of health care infrastructure in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Muscle Relaxant Market Share Analysis

The global muscle relaxant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global muscle relaxant market.

Key players operating in the global muscle relaxant market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Actelion Pharmaceuticals Ltd (Switzerland
• Endo International Inc (Ireland)
• Sandoz International GmbH (Switzerland)

研究方法：全球肌肉松弛剂市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（Factbook）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

SKU-55651